NASDAQ: OCXOncocyte Corp Stock
$3.19+0.14 (+4.59%)
Updated Sep 6, 2024
OCX Price
$3.19
Fair Value Price
N/A
Market Cap
$42.65M
52 Week Low
$2.08
52 Week High
$4.34
P/E
0x
P/B
1.88x
P/S
37.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.02M
Earnings
-$36.35M
Gross Margin
8.1%
Operating Margin
-3,546.43%
Profit Margin
-3,592.1%
Debt to Equity
2.29
Operating Cash Flow
-$17M
Beta
1.19
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OCX Overview
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCX is good value based on its book value relative to its share price (1.88x), compared to the US Diagnostics & Research industry average (4.49x)
P/B vs Industry Valuation
OCX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OCX due diligence checks available for Premium users.
Be the first to know about important OCX news, forecast changes, insider trades & much more!
OCX News
Valuation
OCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
36.74x
Market
24.57x
OCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
4.49x
OCX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCX's financial health
Profit margin
Revenue
$104.0k
Net Income
-$4.5M
Profit Margin
-4,355.8%
OCX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$74.7M
Liabilities
$52.0M
Debt to equity
2.29
OCX's short-term assets ($9.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCX's long-term liabilities ($44.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$191.0k
Financing
$9.8M
OCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCX vs Diagnostic & Research Stocks
Oncocyte Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.